Fig. 4From: Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patientsPercentage of EM patients reporting a migraine during a day from Day 1 to 7. Day 1 is the day of injection of study medications. Pā<ā0.05 for difference with placebo from Day 1ā7 for fremanezumab quarterly and from Day 2ā7 for fremanezumab monthlyBack to article page